The Therapeutic Effect of Thalidomide in Syringomyelia

Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage.

NCT Number	NCT06268093
Lead Sponsor	Xuanwu Hospital, Beijing
Conditions	Syringomyelia, Thalidomide
Enrollment	30 participants
Start Date	2024-02
Primary Completion	2027-02 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2024-02-20